<SEC-DOCUMENT>0001213900-21-052746.txt : 20211014
<SEC-HEADER>0001213900-21-052746.hdr.sgml : 20211014
<ACCEPTANCE-DATETIME>20211014083034
ACCESSION NUMBER:		0001213900-21-052746
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211014
FILED AS OF DATE:		20211014
DATE AS OF CHANGE:		20211014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		211322532

	BUSINESS ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		ALTER POSTPLATZ 2
		CITY:			STANS
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea148843-6k_nlspharma.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of October 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-39957</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>NLS PHARMACEUTICS LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Alter Postplatz 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CH-6370 Stans, Switzerland </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">The Registrant
issued a press release titled: &ldquo;NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to
Treat Chronic Fatigue Associated With Long-COVID.&rdquo; A copy of this press release is furnished herewith as exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea148843ex99-1_nlspharma.htm">Press release titled: &ldquo;NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID.&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 14, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea148843ex99-1_nlspharma.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING THE POTENTIAL OF NLS-4 (LAUFLUMIDE) TO TREAT CHRONIC FATIGUE ASSOCIATED WITH LONG-COVID."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #009BBB"><B>NLS Pharmaceutics Announces Preclinical Data Demonstrating
the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #009BBB"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Switzerland/Stans, October 14, 2021</B> - NLS
Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (&ldquo;NLS&rdquo; or the &ldquo;Company&rdquo;), a Swiss clinical-stage biopharmaceutical company
focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,
announces preclinical data for <FONT STYLE="background-color: white">NLS-4 (Lauflumide), the Company&rsquo;s next-generation wake-promoting
drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-COVID (also known as &ldquo;chronic
COVID syndrome&rdquo;). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #666666">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">NLS sponsored
the preclinical study in which rats that had undergone a procedure to induce chronic fatigue recovered following treatment with NLS-4
and were able to exhibit typical nighttime activity when rats are normally active. </FONT>Moreover, the NLS-4 treated rats had greater
motor-stimulating behavior compared to rats treated with modafinil, a leading drug treatment indicated for extreme fatigue and sleepiness.
Additionally, nighttime activity in NLS-4 treated rats was comparable to rats that did not undergo the fatigue procedure, the study&rsquo;s
control group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #666666">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The fatigue procedure utilized in this
study induces a disruption in circadian activity, namely a decrease in motor activity during the dark period when rats are normally active,
and an increase in motor activity during the period of light when rats are largely inactive,&rdquo; said Dr. Jean-Charles Bizot, Ph.D.,
research manager of the study and Chief Executive Officer of Key-Obs in Orl&eacute;ans, France. &ldquo;In this preclinical model, we observed
NLS-4&rsquo;s clear motor-stimulating effect, which was superior to the widely prescribed fatigue treatment, modafinil. The motor-stimulating
effect of NLS-4 during the dark period suggests an improvement in recovery from the fatigue procedure and therefore is an indicator of
the drug candidate&rsquo;s potential to treat diseases in which chronic fatigue is a primary symptom.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #666666">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Improvement in stimulation of laboratory animals
with NLS-4, with a beneficial effect on nictemeral rhythm, was reported in 2018 in a prior study conducted by the Department of Physiology,
Faculty of Biology and Medicine, Center for Integrative Genomics, University of Lausanne, Switzerland, which concluded that NLS-4 was
a highly potent wake-promoting drug that does not produce hypersomnia rebound. Additionally, the University of Lausanne study found that
sleep recovery after treatment with NLS-4 is characterized by less slow-wave sleep and delta activity compared to modafinil, suggesting
a lower need for recovery despite longer periods of drug-induced wakefulness. https://www.frontiersin.org/articles/10.3389/fnins.2018.00519/full</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&quot;These data provide additional evidence of
the potential beneficial effects of Lauflumide (NLS-4), which produces a lower need for sleep and better recovery from fatigue by properly
modulating wake-rest activity,&rdquo; said Eric Konofal, M.D., Ph.D., Chief Scientific Officer of NLS. &ldquo;Excess fatigue, disturbed
sleep and concentration are the main symptoms found in patients who have contracted COVID-19, and today, there is no known treatment for
the improvement of Long-COVID symptoms. We are excited to bring this novel compound forward into clinical development, with the potential
ability to offer patients diagnosed with Long-COVID the chance for relief from their chronic fatigue symptoms.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About NLS-4 and Fatigue Symptoms Associated
with Viral Pandemics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NLS-4 is Lauflumide [2 - ((bis (4-fluorophenyl)
methyl) sulfinyl) acetamide], a next-generation selective dopamine reuptake inhibitor. NLS-4 is an enantiomeric form (R-isomer) that is
optically pure with an enantiomeric excess of more than 95% of bis (p-fluoro) phenyl ring-substituted derivative of modafinil (USPTO Patent
Application 20130295196, Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof: patent granted,
2017).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NLS-4 was found to weakly bind with neuropeptide
Y1 (NPY1), as a reverse agonist inhibitor modulating the development of depressive-like behavior and exerting histamine-2 receptor activity,
potentially alleviating neurocognitive disorders. A recent complementary assay profile has demonstrated that NLS-4 may exert inhibitory
activity on ACE2 and Cathepsin L, which offers potential promising treatment for COVID-19 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is important to recall that in the aftermath
of the pandemic of viral influenza with lethargic encephalitis, which had prevailed in Europe from 1915 to 1926, psychostimulants (amphetamine
salts) had been adopted as symptomatic treatment for neurological conditions caused by the virus. Amphetamines exhibited their beneficial
effects on the brain, attention, and fatigue in the patients who received them for treatment. Today, with the Covid-19 pandemic, we are
seeing the emergence of a new form of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) called Long-COVID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">NLS is committed
to initiating clinical development of NLS-4 for the treatment of Long-COVID. The claim of this invention by patent application has been
registered under number EP21305944.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About NLS Pharmaceutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLS
Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing
and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience&reg;
is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol
is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed
with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience&reg; in adult
subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">(mazindol controlled-release) in adult subjects suffering from ADHD. The study
met all primary and secondary endpoints and Nolazol</FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">was
well-tolerated. Quilience&reg; has received Orphan Drug Designations both in the U.S. and in&nbsp;Europe&nbsp;for the treatment of narcolepsy.
Up to 1/3<SUP>rd</SUP> of narcoleptic patients are also diagnosed with ADHD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements
when it discusses the potential benefits of <FONT STYLE="background-color: white">NLS-4 (Lauflumide) for</FONT> sufferers of Long-COVID
and its <FONT STYLE="background-color: white">commitment to initiating clinical development of NLS-4 for the treatment of Long-COVID.
</FONT>These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and
are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated
as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees
whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS'
products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in
real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not
be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce
new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause
the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise
required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events
or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks
and uncertainties affecting NLS is contained under the heading &quot;Risk Factors&quot; in NLS' annual report on Form 20-F filed with
the SEC, which is available on the SEC's website,&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alex Zwyer, CEO: +41 41 618 80 00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations Contact </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cindy Rizzo: +1 908-229-7050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.nlspharmaceutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% .\# 2(  A$! Q$!_\0
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MPHHHI%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
